AURO-MOXIFLOXACIN 400 MG
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG · DIN 02432242 · AURO PHARMA INC
Health Canada status: MARKETED
What is AURO-MOXIFLOXACIN?
AURO-MOXIFLOXACIN 400 MG contains MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02432242, held by AURO PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Nov-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AURO-MOXIFLOXACIN used for?
AURO - MOXIFLOXACIN (moxifloxacin hydrochloride) is indicated for the treatment of adults (≥ 18 years of age) with the following bacterial infections caused by susceptible strains of the designated microorganisms for which treatment is appropriate: Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis, Community acquired pneumonia of mild to moderate severity, Community acquired pneumonia in hospitalized patients, Complicated intra-abdominal infections, and Complicated skin and skin structure infections in hospitalized patients.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02432242 |
|---|---|
| Brand name | AURO-MOXIFLOXACIN |
| Generic / active ingredient | MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG |
| Manufacturer | AURO PHARMA INC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA14 MOXIFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Nov-2015 |
| Original market date | 2015-11-04 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is MOXIFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA14 MOXIFLOXACIN. 8 of 25 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-MOXIFLOXACIN | 400 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02443929 |
| M-MOXIFLOXACIN | 400 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02472791 |
| MOXIFLOXACIN | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02520710 |
| MOXIFLOXACIN | 400 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02462974 |
| MOXIFLOXACIN INJECTION | 400 MG / 250 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02433087 |
| SANDOZ MOXIFLOXACIN | 400 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02383381 |
| TEVA-MOXIFLOXACIN | 400 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02375702 |
| AG-MOXIFLOXACIN | 400 MG | TABLET | ANGITA PHARMA INC. | DORMANT | DIN 02478137 |
| APO-MOXIFLOXACIN | 400 MG | TABLET | APOTEX INC | DORMANT | DIN 02404923 |
| APO-MOXIFLOXACIN HYDROCHLORIDE | 400 MG | TABLET | APOTEX INC | APPROVED | DIN 02517108 |
Who else supplies MOXIFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOXIFLOXACIN appears in 153 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.